Real-world insights into atezolizumab plus bevacizumab, carboplatin, and paclitaxel for advanced non-squamous non-small cell lung cancer.

ABSTRACT:

Background

Atezolizumab plus bevacizumab, carboplatin, and paclitaxel (ABCP) therapy demonstrated superior efficacy in advanced non-squamous non-small cell lung cancer (NSCLC) in the IMpower150 trial. However, real-world evidence on ABCP therapy remains limited. This study aimed to assess the real-world efficacy and safety of ABCP as first-line treatment for advanced non-squamous NSCLC.

Methods

We retrospectively evaluated patients with advanced non-squamous NSCLC who received first-line ABCP therapy at our hospital between February 2019 and December 2021. Overall survival (OS) and progression-free survival (PFS) were estimated using the Kaplan-Meier methods. Objective response rate (ORR) and disease control rate (DCR) were used to evaluate the response.

Results

A tot

SUBMITTER: Kanayama M 

PROVIDER: S-EPMC12541879 | biostudies-literature | 2025 Sep

REPOSITORIES: biostudies-literature